Loading organizations...
Loading organizations...
AI Medical Service: AI software developer assisting endoscopists with real-time detection and classification of gastrointestinal cancers during endoscopy.
Based in Tokyo, Japan, AI Medical Service develops artificial intelligence software that assists physicians in detecting early-stage gastrointestinal cancers during endoscopic procedures. The company's technology analyzes real-time endoscopic video to classify lesions and reduce diagnostic oversights across hospital gastroenterology departments and specialized clinics. The enterprise currently partners with over 100 medical institutions, including recognizable facilities like the Cancer Institute Hospital, the University of Tokyo Hospital, and National University Hospital Singapore. AI Medical Service has raised over $100 million in total funding, which includes a $70 million Series C round led by SoftBank Vision Fund 2 alongside Globis Capital Partners and other institutional investors. The firm recently secured regulatory approval from Japan's Ministry of Health, Labour and Welfare to commercialize its gastroAI model-G diagnostic support system for concurrent gastric cancer. The organization was founded in 2017 by Dr. Tomohiro Tada.
AI Medical Service has raised $105.9M across 2 funding rounds.
AI Medical Service has raised $105.9M in total across 2 funding rounds.
AI Medical Service has raised $105.9M in total across 2 funding rounds.
AI Medical Service's investors include SoftBank, Incubate Fund, World Innovation Lab, Gen Tsuchikawa, Masataka Matsumoto.
AI Medical Service has raised $105.9M across 2 funding rounds. Most recently, it raised $63.0M Series C in May 2022.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| May 26, 2022 | $63.0M Series C | SoftBank | Incubate Fund, World Innovation Lab |
| Oct 4, 2019 | $42.9M Series B | Gen Tsuchikawa, Masataka Matsumoto |